Just two days after Novo Nordisk launched Wegovy (semaglutide 2.4 mg) in India, Eli Lilly received regulatory approval for the KwikPen® format of its rival therapy Mounjaro (tirzepatide) ...

Weight-loss jabs are the “talk of the House of Commons tea rooms” and “half my colleagues are on them”, the Health Secretary ...

US pharma giant Eli Lilly has secured Indian regulatory approval to market Mounjaro, its widely used diabetes and weight-loss ...

Eli Lillys Mounjaro KwikPen gains approval in India, targeting diabetes and obesity with its dual-action formula for weight ...

Eli Lilly announced that its breakthrough drug, Mounjaro (tirzepatide), has received marketing authorization from India’s ...

With Novo Nordisk’s Wegovy already in the market, Eli Lilly is stepping up its game with a patient-friendly pen device, ...

Eli Lilly will soon launch Mounjaro KwikPen in India. This follows regulatory approval for the diabetes and obesity drug. The ...

Eli Lilly receives approval for Mounjaro in prefilled Kwikpen as competition intensifies in India's weight-loss drug market ...

Eli Lilly's once-weekly KwikPen format for Mounjaro has been approved in India, offering an easier delivery system for type 2 ...

Eli Lilly and Novo Nordisk intensify their weight-loss drug rivalry in India as rising demand and looming generics reshape a ...

India's anti-obesity drug market is currently valued at Rs 3,000-3,500 crore & is projected to grow nearly eightfold by 2030, according to market estimates.

Mounjaro has released once-weekly injections that are helpful in managing type 2 diabetes along with showing remarkable ...